Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. scores highest on Nitro (78) and lowest on Price (10). Its PosiPenta is 45.10 out of 100, around the middle of similar companies.
On the Penta Grid this week, Spyre Therapeutics, Inc. is Grid #380 of 837 in the Healthcare sector in United States, and Grid #2,409 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Spyre Therapeutics, Inc. | 45.10 | 10 | 21 | 78 | 76 | 40 |
| Cytokinetics, Incorporated | 49.29 | 0 | 30 | 61 | 97 | 59 |
| Bruker Corporation | 60.55 | 19 | 76 | 82 | 48 | 78 |
| ImmunityBio, Inc. | 64.03 | 0 | 61 | 80 | 96 | 83 |
| Hinge Health, Inc. | 62.78 | 22 | 56 | 94 | 82 | 60 |
| HealthEquity, Inc. | 64.75 | 36 | 84 | 81 | 58 | 65 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -41.61 |
| P/B ratio | 6.78 |
EEarnings
| Trailing EPS | ₹-181.85 |
| Forward EPS | ₹-333.61 |
NNitro
| Price | 7567.72 |
| 52-week high | 10435.22 |
| 52-week low | 2002.75 |
| Fall from 52-week high | 27.5% |
TTorque
| Return on equity (ROE) | -22.98% |
| Debt-to-equity | 0.00 |
AAnchor
| Beta (price swings) | 3.11 |
| Market cap | ₹70,721 Cr |
| Insider holding | 1.58% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Spyre Therapeutics, Inc.'s PosiPenta score?
Spyre Therapeutics, Inc.'s PosiPenta is 45.10 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Spyre Therapeutics, Inc. stand on the Penta Grid?
On the Penta Grid this week, Spyre Therapeutics, Inc. is Grid #380 of 837 in the Healthcare sector in United States, and Grid #2,409 of 4,000 in United States.
Which PosiPenta pillar is strongest for Spyre Therapeutics, Inc.?
Nitro (momentum), with a score of 78 out of 100: better than most similar companies.
Which PosiPenta pillar is weakest for Spyre Therapeutics, Inc.?
Price (valuation), with a score of 10 out of 100: much weaker than most similar companies.
Has Spyre Therapeutics, Inc.'s PosiPenta changed since last week?
Yes, it rose 2.86 points, from 42.24 to 45.10.
PositoAI is for research and education only and is not investment advice.